Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
Nat Commun ; 15(1): 352, 2024 Jan 08.
Article in English | MEDLINE | ID: mdl-38191557

ABSTRACT

Heterogeneous response to Enzalutamide, a second-generation androgen receptor signaling inhibitor, is a central problem in castration-resistant prostate cancer (CRPC) management. Genome-wide systems investigation of mechanisms that govern Enzalutamide resistance promise to elucidate markers of heterogeneous treatment response and salvage therapies for CRPC patients. Focusing on the de novo role of MYC as a marker of Enzalutamide resistance, here we reconstruct a CRPC-specific mechanism-centric regulatory network, connecting molecular pathways with their upstream transcriptional regulatory programs. Mining this network with signatures of Enzalutamide response identifies NME2 as an upstream regulatory partner of MYC in CRPC and demonstrates that NME2-MYC increased activities can predict patients at risk of resistance to Enzalutamide, independent of co-variates. Furthermore, our experimental investigations demonstrate that targeting MYC and its partner NME2 is beneficial in Enzalutamide-resistant conditions and could provide an effective strategy for patients at risk of Enzalutamide resistance and/or for patients who failed Enzalutamide treatment.


Subject(s)
Drug Resistance, Neoplasm , Prostatic Neoplasms, Castration-Resistant , Humans , Male , Androgen Receptor Antagonists , Benzamides , NM23 Nucleoside Diphosphate Kinases , Prostatic Neoplasms, Castration-Resistant/drug therapy , Prostatic Neoplasms, Castration-Resistant/genetics , Signal Transduction
2.
Comput Struct Biotechnol J ; 20: 583-597, 2022.
Article in English | MEDLINE | ID: mdl-35116134

ABSTRACT

High-risk pediatric B-ALL patients experience 5-year negative event rates up to 25%. Although some biomarkers of relapse are utilized in the clinic, their ability to predict outcomes in high-risk patients is limited. Here, we propose a random survival forest (RSF) machine learning model utilizing interpretable genomic inputs to predict relapse/death in high-risk pediatric B-ALL patients. We utilized whole exome sequencing profiles from 156 patients in the TARGET-ALL study (with samples collected at presentation) further stratified into training and test cohorts (109 and 47 patients, respectively). To avoid overfitting and facilitate the interpretation of machine learning results, input genomic variables were engineered using a stepwise approach involving univariable Cox models to select variables directly associated with outcomes, genomic coordinate-based analysis to select mutational hotspots, and correlation analysis to eliminate feature co-linearity. Model training identified 7 genomic regions most predictive of relapse/death-free survival. The test cohort error rate was 12.47%, and a polygenic score based on the sum of the top 7 variables effectively stratified patients into two groups, with significant differences in time to relapse/death (log-rank P = 0.001, hazard ratio = 5.41). Our model outperformed other EFS modeling approaches including an RSF using gold-standard prognostic variables (error rate = 24.35%). Validation in 174 standard-risk patients and 3 patients who failed to respond to induction therapy confirmed that our RSF model and polygenic score were specific to high-risk disease. We propose that our feature selection/engineering approach can increase the clinical interpretability of RSF, and our polygenic score could be utilized for enhance clinical decision-making in high-risk B-ALL.

3.
Technol Cancer Res Treat ; 20: 15330338211027906, 2021.
Article in English | MEDLINE | ID: mdl-34190006

ABSTRACT

PURPOSE/OBJECTIVE(S): The additional personnel and imaging procedures required for Adaptive Radiation Therapy (ART) pose a challenge for a broad implementation. We hypothesize that a change in transit fluence during the treatment course is correlated with the change of quality of life and thus can be used as a replanning trigger. MATERIALS/METHODS: Twenty-one head and neck cancer (HNC) patients filled out an MD Anderson Dysphagia Inventory (MDADI) questionnaire, before-and-after the radiotherapy treatment course. The transit fluence was measured by the Watchdog (WD) in-vivo portal dosimetry system. The patients were monitored with daily WD and weekly CBCTs. The region of interest (ROI) of each patient was defined as the outer contour of the patient between approximate spine levels C1 to C4, essentially the neck and mandible inside the beam's eye view. The nth day integrated transit fluence change, Δϕn, and the volume change, ΔVROI, of the ROI of each patient was calculated from the corresponding WD and CBCT measurements. The correlation between MDADI scores and age, gender, planning mean dose to salivary glands , weight change ΔW, ΔVROI, and Δϕn, were analyzed using the ranked-Pearson correlation. RESULTS: No statistically significant correlation was found for age, gender and ΔW. was found to have clinically important correlation with functional MDADI (ρ = -0.39, P = 0.081). ΔVROI was found to have statistically significant correlation of 0.44, 0.47 and 0.44 with global, physical and functional MDADI (P-value < 0.05). Δϕn was found to have statistically significant ranked-correlation (-0.46, -0.46 and -0.45) with physical, functional and total MDADI (P-value < 0.05). CONCLUSION: A transit fluence based decision support metric (DSM) is statistically correlated with the dysphagia risk. It can not only be used as an early signal in assisting clinicians in the ART patient selection for replanning, but also lowers the resource barrier of ART implementation.


Subject(s)
Deglutition Disorders/etiology , Head and Neck Neoplasms/radiotherapy , Quality of Life , Adult , Aged , Aged, 80 and over , Dose Fractionation, Radiation , Female , Humans , Male , Middle Aged , Patient Reported Outcome Measures , Pharyngeal Muscles , Radiation Dosage , Radiotherapy Planning, Computer-Assisted , Risk Assessment/methods , Salivary Glands , Xerostomia/etiology
4.
EBioMedicine ; 61: 103047, 2020 Nov.
Article in English | MEDLINE | ID: mdl-33099086

ABSTRACT

BACKGROUND: Prioritization of breast cancer patients based on the risk of resistance to tamoxifen plays a significant role in personalized therapeutic planning and improving disease course and outcomes. METHODS: In this work, we demonstrate that a genome-wide pathway-centric computational framework elucidates molecular pathways as markers of tamoxifen resistance in ER+ breast cancer patients. In particular, we associated activity levels of molecular pathways with a wide spectrum of response to tamoxifen, which defined markers of tamoxifen resistance in patients with ER+ breast cancer. FINDINGS: We identified five biological pathways as markers of tamoxifen failure and demonstrated their ability to predict the risk of tamoxifen resistance in two independent patient cohorts (Test cohort1: log-rank p-value = 0.02, adjusted HR = 3.11; Test cohort2: log-rank p-value = 0.01, adjusted HR = 4.24). We have shown that these pathways are not markers of aggressiveness and outperform known markers of tamoxifen response. Furthermore, for adoption into clinic, we derived a list of pathway read-out genes and their associated scoring system, which assigns a risk of tamoxifen resistance for new incoming patients. INTERPRETATION: We propose that the identified pathways and their read-out genes can be utilized to prioritize patients who would benefit from tamoxifen treatment and patients at risk of tamoxifen resistance that should be offered alternative regimens. FUNDING: This work was supported by the Rutgers SHP Dean's research grant, Rutgers start-up funds, Libyan Ministry of Higher Education and Scientific Research, and Katrina Kehlet Graduate Award from The NJ Chapter of the Healthcare Information Management Systems Society.


Subject(s)
Biomarkers, Tumor , Breast Neoplasms/etiology , Breast Neoplasms/metabolism , Drug Resistance, Neoplasm/genetics , Receptors, Estrogen/metabolism , Signal Transduction , Antineoplastic Agents, Hormonal/pharmacology , Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Female , Gene Expression Regulation, Neoplastic , Genome-Wide Association Study/methods , Humans , ROC Curve , Receptors, Estrogen/genetics , Tamoxifen/pharmacology , Tamoxifen/therapeutic use
5.
J Am Coll Nutr ; 38(8): 722-728, 2019.
Article in English | MEDLINE | ID: mdl-31063433

ABSTRACT

Objective: Celiac disease is a genetic disease affecting people of all ages, resulting in small intestine enteropathy. It is considered to be a clinical chameleon. Average prevalence of celiac disease is 1 out of 100 people with data indicating the risk may be as high as 22% for those with first-degree relatives with the disease. Eighty-three percent of people with celiac disease may be undiagnosed. Average duration to diagnosis is 10 years. Data indicate that there is a lack of consensus regarding diagnostics and symptomatology.Method: A clinical decision support system (CDSS) was developed using Exsys Corvid for expert analysis (CD-CDSS). The CD-CDSS was divided into symptoms and manifestations with 80 points of navigation, and a serology section, and was validated by 13 experts in the field of celiac disease using a 10-statement 5-point Likert scale.Results: This scale was analyzed using Cronbach's alpha reliability coefficient, which was calculated using SPSS and revealed good internal consistency and reliability with a result of 0.813. One hundred percent of experts agreed that the CD-CDSS is capable of guiding a health care professional through the diagnostic process, contains an accurate list of symptoms based on the clinical literature, and can foster improved awareness and education about celiac disease and that there is a need for this system.Conclusions: A celiac disease risk estimation and decision-making expert system was successfully developed and evaluated by medical professionals, with 100% agreeing that this CD-CDSS is medically accurate and can guide health care professionals through the diagnostic process.


Subject(s)
Celiac Disease/diagnosis , Decision Making , Expert Systems , Physicians , Autoantibodies/blood , Biopsy , Celiac Disease/blood , Celiac Disease/pathology , Humans , Reproducibility of Results , Risk Factors
6.
J Histochem Cytochem ; 66(12): 889-902, 2018 12.
Article in English | MEDLINE | ID: mdl-30138043

ABSTRACT

Striking levels of spatial organization exist among and within interphase cell chromosomes, raising the possibility that other nuclear molecular components may also be organized in ways that facilitate nuclear function. To further examine molecular distributions and organization within cell nuclei, we utilized Raman spectroscopy to map distributions of molecular components, with a focus on cellular lipids. Although the vast majority of cellular lipids are associated with membranes, mapping the 2870/2850 cm-1 lipid peak ratios revealed that the most highly ordered lipids within interphase cells are found within cell nuclei. This finding was seen in cells from multiple tissue types, noncancerous cells, and in cancer cell lines of different metastatic potential. These highly ordered lipids colocalize with nuclear chromatin, are present throughout the nuclear volume, and remain colocalized with chromatin through mitosis, when the nuclear envelope has dissociated. Phosphatidylinositol is a major component of the highly ordered lipids. The presence of phosphatidylinositol and other lipids in the nuclear interior is well established, but their highly ordered packing has not been reported and represents a unique finding. The molecular interactions involved in the formation and maintenance of these highly ordered lipids, and their potential effects on nuclear activities, remain to be discovered.


Subject(s)
Cell Nucleus/chemistry , Lipids/analysis , Spectrum Analysis, Raman/methods , Cell Line, Tumor , Cell Nucleus/ultrastructure , Humans , Imaging, Three-Dimensional/methods , Interphase , Microscopy, Confocal/methods , Mitosis , Phospholipids/analysis
7.
Sci Signal ; 10(471)2017 Mar 21.
Article in English | MEDLINE | ID: mdl-28325822

ABSTRACT

Chemokines orchestrate cell migration for development, immune surveillance, and disease by binding to cell surface heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptors (GPCRs). The array of interactions between the nearly 50 chemokines and their 20 GPCR targets generates an extensive signaling network to which promiscuity and biased agonism add further complexity. The receptor CXCR4 recognizes both monomeric and dimeric forms of the chemokine CXCL12, which is a distinct example of ligand bias in the chemokine family. We demonstrated that a constitutively monomeric CXCL12 variant reproduced the G protein-dependent and ß-arrestin-dependent responses that are associated with normal CXCR4 signaling and lead to cell migration. In addition, monomeric CXCL12 made specific contacts with CXCR4 that are not present in the structure of the receptor in complex with a dimeric form of CXCL12, a biased agonist that stimulates only G protein-dependent signaling. We produced an experimentally validated model of an agonist-bound chemokine receptor that merged a nuclear magnetic resonance-based structure of monomeric CXCL12 bound to the amino terminus of CXCR4 with a crystal structure of the transmembrane domains of CXCR4. The large CXCL12:CXCR4 protein-protein interface revealed by this structure identified previously uncharacterized functional interactions that fall outside of the classical "two-site model" for chemokine-receptor recognition. Our model suggests a mechanistic hypothesis for how interactions on the extracellular face of the receptor may stimulate the conformational changes required for chemokine receptor-mediated signal transduction.


Subject(s)
Chemokine CXCL12/chemistry , Protein Multimerization , Receptors, CXCR4/chemistry , Signal Transduction , Amino Acid Sequence , Cell Line, Tumor , Cell Movement/genetics , Chemokine CXCL12/genetics , Chemokine CXCL12/metabolism , HEK293 Cells , Humans , Magnetic Resonance Spectroscopy , Models, Molecular , Mutation , Protein Binding , Receptors, CXCR4/genetics , Receptors, CXCR4/metabolism , beta-Arrestin 2/genetics , beta-Arrestin 2/metabolism
8.
J Pathol Inform ; 6: 29, 2015.
Article in English | MEDLINE | ID: mdl-26110096

ABSTRACT

The digitization of images has not only led to increasingly sophisticated methods of quantitating information from those images themselves, but also to the development of new physics-based techniques for extracting information from the original specimen and presenting this as visual data in both two and three-dimensional (3D) forms. This evolution of an image-based discipline has reached maturity in Radiology, but it is only just beginning in Pathology. An historical perspective is provided both on the current state of computational imaging in pathology and of the factors that are impeding further progress in the development and application of these approaches. Emphasis is placed on barriers to the dissemination of information in this area. The value of computational imaging in basic and translational research is clear. However, while there are many examples of "virtual diagnostics" in Radiology, there are only relatively few in Pathology. Nevertheless, we can do cellular level analysis of lesions accessible by endoscopic or catheterization procedures, and a number of steps have been taken toward real-time imaging as adjuncts to traditional biopsies. Progress in computational imaging will greatly expand the role of pathologists in clinical medicine as well as research.

9.
Cytokine ; 69(1): 47-55, 2014 Sep.
Article in English | MEDLINE | ID: mdl-25022961

ABSTRACT

Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that was initially identified by its ability to inhibit the movement of macrophages. Cell migration is a highly complex process involving changes to the cytoskeleton and cell adhesion molecules, and is regulated by the Rho GTPases. A simple model using human monocytic U-937 cells to elicit the classic MIF response was implemented to examine the mechanism of MIF-induced migration inhibition. Our results demonstrate that MIF inhibits migration of these U-937 cells through a non-canonical receptor, CXCR4, in the absence of the putative primary MIF receptor CD74. Migration inhibition is dependent upon a series of temporal perturbations of the activities of the Rho GTPases: initial activation followed by subsequent inactivation of RhoA, inactivation of Rac1, and cyclic activation of Cdc42. MIF-mediated changes in the activities of the Rho GTPases jointly contributed to migration inhibition in these cells. Collectively, these data suggest that the MIF-mediated migration inhibition is mediated by the outcome of G-protein signaling, and in less adherent cells such as those of the monocyte/macrophage lineage, RhoA directly affects net translocation through its ability to induce cell body contraction. These findings demonstrate that CXCR4 can mediate MIF signaling in the absence of CD74 in addition to serving as a MIF co-receptor along with CD74. These results correlate MIF activity to specific and sequential Rho GTPase activity perturbations, and given that CXCR4 functions in numerous processes, suggests potential roles for the modulation of cell movement in those events including development, cell survival and viral infection.


Subject(s)
Intramolecular Oxidoreductases/metabolism , Macrophage Migration-Inhibitory Factors/metabolism , Macrophages/immunology , Monocytes/immunology , Receptors, CXCR4/metabolism , rhoA GTP-Binding Protein/metabolism , Antigens, Differentiation, B-Lymphocyte/metabolism , Cell Adhesion Molecules/metabolism , Cell Line, Tumor , Cell Movement/immunology , Enzyme Activation , GTPase-Activating Proteins/metabolism , HEK293 Cells , Histocompatibility Antigens Class II/metabolism , Humans , Phosphoproteins/metabolism , Receptors, CXCR4/antagonists & inhibitors , Receptors, Interleukin-8B/metabolism , Signal Transduction , U937 Cells , rac1 GTP-Binding Protein/metabolism
10.
PLoS One ; 8(5): e62491, 2013.
Article in English | MEDLINE | ID: mdl-23671604

ABSTRACT

The glycoprotein YKL-40 (CHI3L1) is a secreted chitinase family protein that induces angiogenesis, cell survival, and cell proliferation, and plays roles in tissue remodeling and immune regulation. It is expressed primarily in cells of mesenchymal origin, is overexpressed in numerous aggressive carcinomas and sarcomas, but is rarely expressed in normal ectodermal tissues. Bone marrow-derived mesenchymal stem cells (MSCs) can be induced to differentiate into various mesenchymal tissues and trans-differentiate into some non-mesenchymal cell types. Since YKL-40 has been used as a mesenchymal marker, we followed YKL-40 expression as undifferentiated MSCs were induced to differentiate into bone, cartilage, and neural phenotypes. Undifferentiated MSCs contain significant levels of YKL-40 mRNA but do not synthesize detectable levels of YKL-40 protein. MSCs induced to differentiate into chondrocytes and osteocytes soon began to express and secrete YKL-40 protein, as do ex vivo cultured chondrocytes and primary osteocytes. In contrast, MSCs induced to trans-differentiate into neurons did not synthesize YKL-40 protein, consistent with the general absence of YKL-40 protein in normal CNS parenchyma. However, these trans-differentiated neurons retained significant levels of YKL-40 mRNA, suggesting the mechanisms which prevented YKL-40 translation in undifferentiated MSCs remained in place, and that these trans-differentiated neurons differ in at least this way from neurons derived from neuronal stem cells. Utilization of a differentiation protocol containing ß-mercaptoethanol resulted in cells that expressed significant amounts of intracellular YKL-40 protein that was not secreted, which is not seen in normal cells. Thus the synthesis of YKL-40 protein is a marker for MSC differentiation into mature mesenchymal phenotypes, and the presence of untranslated YKL-40 mRNA in non-mesenchymal cells derived from MSCs reflects differences between differentiated and trans-differentiated phenotypes.


Subject(s)
Adipokines/genetics , Cell Differentiation/genetics , Cell Transdifferentiation/genetics , Lectins/genetics , Mesenchymal Stem Cells/metabolism , Adipokines/metabolism , Blotting, Western , Bone Marrow Cells/cytology , Bone Marrow Cells/metabolism , Cells, Cultured , Chitinase-3-Like Protein 1 , Chondrocytes/cytology , Chondrocytes/metabolism , Gene Expression , Humans , Lectins/metabolism , Mesenchymal Stem Cells/cytology , Neurons/cytology , Neurons/metabolism , Osteocytes/cytology , Osteocytes/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction
11.
Nucleic Acids Res ; 41(10): 5321-40, 2013 May 01.
Article in English | MEDLINE | ID: mdl-23571757

ABSTRACT

Telomere integrity is critical for telomere function and genomic stability. We previously demonstrated that non-erythroid α-spectrin (αIISp) is present in mammalian cell nuclei where it is important in repair of DNA interstrand cross-links (ICLs) and chromosome stability. We now demonstrate that αIISp is also important for telomere maintenance after ICL damage. It localizes to telomeres in S phase after ICL damage where it has enhanced association with TRF1 and TRF2 and is required for recruitment of the ICL repair protein, XPF, to damage-induced foci at telomeres. In telomerase-positive normal cells depleted of αIISp by siRNA or in Fanconi anemia, complementation group A (FA-A) cells, where αIISp levels are 35-40% of normal, ICL damage results in failure of XPF to localize to telomeres, markedly increased telomere dysfunction-induced foci, followed by catastrophic loss of telomeres. Restoration of αIISp levels to normal in FA-A cells corrects these deficiencies. Our studies demonstrate that αIISp is critical for repair of DNA ICLs at telomeres, likely by facilitating the recruitment of repair proteins similar, but not identical, to its proposed role in repair of DNA ICLs in genomic DNA and that this function in turn is critical for telomere maintenance after DNA ICL damage.


Subject(s)
DNA Damage , DNA Repair , Spectrin/physiology , Telomere/physiology , Cell Line , Chromosome Aberrations , Cross-Linking Reagents/toxicity , DNA-Binding Proteins/analysis , Fanconi Anemia Complementation Group D2 Protein/analysis , Humans , S Phase/genetics , Spectrin/antagonists & inhibitors , Spectrin/metabolism , Telomere/chemistry , Telomere/metabolism , Telomeric Repeat Binding Protein 1/metabolism , Telomeric Repeat Binding Protein 2/metabolism
12.
Stud Health Technol Inform ; 185: 185-205, 2013.
Article in English | MEDLINE | ID: mdl-23542936

ABSTRACT

Biological organisms and their component organs, tissues and cells have unique electrical impedance properties. Impedance properties often change with changes in structure, composition, and metabolism, and can be indicative of the onset and progression of disease states. Over the past 100 years, instruments and analytical methods have been developed to measure the impedance properties of biological specimens and to utilize these measurements in both clinical and basic science settings. This chapter will review the applications of impedance measurements in the biomedical sciences, from whole body analysis to impedance measurements of single cells and cell monolayers, and how cellular impedance measuring instruments can now be used in high throughput screening applications.


Subject(s)
Cell Physiological Phenomena , Diagnosis, Computer-Assisted/instrumentation , Diagnosis, Computer-Assisted/methods , Electric Impedance , Plethysmography, Impedance/instrumentation , Plethysmography, Impedance/methods , Animals , Humans
13.
Anal Cell Pathol (Amst) ; 36(5-6): 117-24, 2013.
Article in English | MEDLINE | ID: mdl-23334553

ABSTRACT

Science advances both by conceptual leaps and by improved observational and analytic tools. Mechanism and function in biological systems can best be understood in the context of the complex microenvironments in which they occur, and for this purpose morphologic analysis can be critical. Technological advances in cell and tissue imaging are currently finding application in a wide variety of basic, translational, and clinical biomedical studies. "Biophotonics in Pathology" was designed as a multi-authored work to describe the various kinds of imaging strategies that have been developed as computational power keeps increasing. Some of these overlap with radiologic techniques and others do not. The field is continuously evolving, and in this commentary I will touch on additional techniques for morphology-based interrogation of cells and tissues that have recently been described. However, it is important to note that though we are expanding our armamentarium as pathologists, our radiological colleagues have been doing this for many years. Clearly, they have embraced new imaging techniques to a greater extent than have pathologists. This commentary discusses some of the factors responsible for this, and suggests that pathology and radiology are converging towards a more holistic approach to diagnostic imaging.

14.
Anal Cell Pathol (Amst) ; 35(5-6): 363-74, 2012.
Article in English | MEDLINE | ID: mdl-22941962

ABSTRACT

Biological organisms and their component organs, tissues and cells have unique electrical impedance properties. Impedance properties often change with changes in structure, composition, and metabolism, and can be indicative of the onset and progression of disease states. Over the past 100 years, instruments and analytical methods have been developed to measure the impedance properties of biological specimens and to utilize these measurements in both clinical and basic science settings. This chapter will review the applications of impedance measurements in the biomedical sciences, from whole body analysis to impedance measurements of single cells and cell monolayers, and how cellular impedance measuring instruments can now be used in high throughput screening applications.


Subject(s)
Biomedical Research/methods , Animals , Body Composition , Cells/metabolism , Electric Impedance , Humans , Organ Specificity
15.
Anal Cell Pathol (Amst) ; 34(6): 355-61, 2011.
Article in English | MEDLINE | ID: mdl-22045277

ABSTRACT

The interaction of the origin recognition complex (ORC) with replication origins is a critical parameter in eukaryotic replication initiation. In mammals the ORC remains bound except during mitosis, thus the localization of ORC complexes allows localization of origins. A monoclonal antibody that recognizes human ORC1 was used to localize ORC complexes in populations of human MOLT-4 cells separated by cell cycle position using centrifugal elutriation. ORC1 staining in cells in early G1 is diffuse and primarily peripheral. As the cells traverse G1, ORC1 accumulates and becomes more localized towards the center of the nucleus, however around the G1/S boundary the staining pattern changes and ORC1 appears peripheral. By mid to late S phase ORC1 immunofluorescence is again concentrated at the nuclear center. During anaphase, ORC1 staining is localized mainly in the pericentriolar regions. These findings suggest that concerted movements of origin DNA sequences in addition to the previously documented assembly and disassembly of protein complexes are an important aspect of replication initiation loci in eukaryotes.


Subject(s)
Cell Cycle , Leukemia/metabolism , Leukemia/pathology , Origin Recognition Complex/metabolism , Cell Line, Tumor , Centrifugation , Centrioles/metabolism , Centrioles/pathology , DNA, Neoplasm/metabolism , Flow Cytometry , Fluorescent Antibody Technique , G1 Phase , G2 Phase , Humans , Protein Transport , S Phase
16.
Anal Cell Pathol (Amst) ; 34(5): 225-34, 2011.
Article in English | MEDLINE | ID: mdl-21988886

ABSTRACT

Despite significant differences in genetic profiles, cancer cells share common phenotypic properties, including membrane-associated changes that facilitate invasion and metastasis. The Corning Epic optical biosensor was used to monitor dynamic mass rearrangements within and proximal to the cell membrane in tumor cell lines derived from cancers of the colon, bone, cervix, lung and breast. Data was collected in real time and required no exogenously added signaling moiety (signal-free technology). Cell lines displayed unique profiles over the time-courses: the time-courses all displayed initial signal increases to maximal values, but the rate of increase to those maxima and the value of those maxima were distinct for each cell line. The rate of decline following the maxima also differed among cell lines. There were correlations between the signal maxima and the observed metastatic behavior of the cells in xenograft experiments; for most cell types the cells that were more highly metastatic in mice had lower time-course maxima values, however the reverse was seen in breast cancer cells. The unique profiles of these cell lines and the correlation of at least one profile characteristic with metastatic behavior demonstrate the potential utility of biophysical tumor cell profiling in the study of cancer biology.


Subject(s)
Biosensing Techniques , Cell Membrane/pathology , Neoplasms/pathology , Animals , CHO Cells , Cricetinae , Cricetulus , HT29 Cells , HeLa Cells , Humans , Mice , Neoplasm Invasiveness , Neoplasm Metastasis , Phenotype , Reproducibility of Results , Time Factors , Transplantation, Heterologous
17.
Mol Cancer Ther ; 8(9): 2684-92, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19723889

ABSTRACT

Alterations in the human 13q14 genomic region containing microRNAs mir-15a and mir-16-1 are present in most human chronic lymphocytic leukemia (CLL). We have previously found the development of CLL in the New Zealand Black murine model to be associated with a point mutation in the primary mir-15a/16-1 region, which correlated with a decrease in mature miR-16 and miR-15a levels. In this study, addition of exogenous miR-15a and miR-16 led to an accumulation of cells in G(1) in non-New Zealand Black B cell and New Zealand Black-derived malignant B-1 cell lines. However, the New Zealand Black line had significantly greater G(1) accumulation, suggesting a restoration of cell cycle control upon exogenous miR-15a/16 addition. Our experiments showed a reduction in protein levels of cyclin D1, a miR-15a/16 target and cell cycle regulator of G(1)/S transition, in the New Zealand Black cell line following miR-15a/16 addition. These microRNAs were shown to directly target the cyclin D1 3' untranslated region using a green fluorescent protein lentiviral expression system. miR-16 was also shown to augment apoptosis induction by nutlin, a mouse double minute 2 (MDM2) antagonist, and genistein, a tyrosine kinase inhibitor, when added to a B-1 cell line derived from multiple in vivo passages of malignant B-1 cells from New Zealand Black mice with CLL. miR-16 synergized with nutlin and genistein to induce apoptosis. Our data support a role for the mir-15a/16-1 cluster in cell cycle regulation and suggest that these mature microRNAs in both the New Zealand Black model and human CLL may be targets for therapeutic efficacy in this disease.


Subject(s)
Disease Models, Animal , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , MicroRNAs/genetics , Animals , Antineoplastic Agents/pharmacology , Apoptosis , Base Sequence , Cyclin D1/genetics , DNA Primers , Drug Screening Assays, Antitumor , Genistein/therapeutic use , Imidazoles/therapeutic use , Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Mice , Mice, Inbred C57BL , Piperazines/therapeutic use , RNA, Messenger/genetics
18.
Cell Cycle ; 8(16): 2631-42, 2009 Aug 15.
Article in English | MEDLINE | ID: mdl-19633418

ABSTRACT

The function of the relatively well-studied DNA replication origins in the yeast Saccharomyces cerevisiae is dependent upon interactions between origin replication complex (ORC) proteins and several defined origin sequence elements, including the 11 bp ARS consensus sequence (ACS). Although the ORC proteins, as well as numerous other protein components required for DNA replication initiation, are largely conserved between yeast and mammals, DNA sequences within mammalian replication origins are highly variable and sequences homologous to the yeast ACS elements are generally not present. We have previously identified several replication initiation sites within the nontranscribed spacer region of the human ribosomal RNA gene, and found that two highly utilized sites each contain a homologue of the yeast ACS embedded within a DNA unwinding element and a matrix attachment region. Here we examine protein binding within these initiation sites, and demonstrate that these ACS homologues specifically bind the alternate splicing factor SF2/ASF as well as GAPDH in vitro, and present evidence that the SF2/ASF interaction also occurs within the nuclei of intact cells. As the moderate upregulation of SF2/ASF has been linked to oncogenesis through the promotion of alternatively spliced forms of several regulatory proteins, our results suggest an additional mechanism by which SF2/ASF may influence the transformed cell phenotype.


Subject(s)
DNA Replication/genetics , DNA, Ribosomal/genetics , Nuclear Proteins/metabolism , Replication Origin/genetics , Base Sequence , Cell Line , Chromatin Immunoprecipitation , Chromatography, Affinity , DNA, Ribosomal/chemistry , Electrophoretic Mobility Shift Assay , Humans , Molecular Sequence Data , Protein Binding , RNA-Binding Proteins , Serine-Arginine Splicing Factors
19.
Crit Rev Clin Lab Sci ; 45(6): 531-62, 2008.
Article in English | MEDLINE | ID: mdl-19003601

ABSTRACT

Chitinase 3-Like-1 (CHI3L1) is a secreted 40 kDa glycoprotein that is upregulated in a number of human cancers and in non-neoplastic disease states characterized by chronic inflammation and tissue remodeling. Increased serum levels of CHI3L1 parallel disease severity, poorer prognosis, and shorter survival in many human neoplasias, including cancers of the breast, colon, prostate, ovaries, brain, thyroid, lung, and liver. Increased serum CHI3L1 also correlates with disease severity in rheumatoid arthritis, osteoarthritis, liver fibrosis, inflammatory bowel disease, and bacterial septicemia. CHI3L1 is a rheumatoid arthritis (RA) autoantigen, and MHC complexes containing specific CHI3L1 peptides have been found in RA patients; however, intranasal introduction of these same CHI3L1 peptides can induce tolerance towards them. CHI3L1 is a nonhydrolytic member of the human chitinase family that binds chitin tightly and heparin at lower affinity. Interactions with type I collagen, CHI3L1's only known protein-binding partner, helps regulate collagen fibril formation. The principal sources of CHI3L1 are activated macrophages and chondrocytes, neutrophils, and some tissue and tumor cells. CHI3L1 can act as a fibroblast mitogen and can activate several signaling pathways, however, no cell surface-binding partner for CHI3L1 has been identified. The ability of CHI3L1 to bind both proteins and carbohydrates allows potential interactions with a variety of cell-surface and extracellular-matrix proteins, proteoglycans, and polysaccharides, and thus CHI3L1 can interface between proteomics and glycomics.


Subject(s)
Arthritis, Rheumatoid/metabolism , Biomarkers/blood , Glycoproteins/metabolism , Inflammation/metabolism , Models, Molecular , Neoplasms/metabolism , Adipokines , Chitin/metabolism , Chitinase-3-Like Protein 1 , Glycomics/methods , Glycoproteins/blood , Heparin/metabolism , Humans , Lectins , Proteomics/methods
20.
Br J Haematol ; 139(5): 645-57, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17941951

ABSTRACT

Mouse models are valuable tools in the study of human chronic lymphocytic leukaemia (CLL). The New Zealand Black (NZB) strain is a naturally occurring model of late-onset CLL characterized by B-cell hyperproliferation and autoimmunity early in life, followed by progression to CLL. Other genetically engineered models of CLL that have been developed include (NZB x NZW) F1 mice engineered to express IL5, mice expressing human TCL1A, and mice overexpressing both BCL2 and a tumour necrosis factor receptor-associated factor. The applicability to human CLL varies with each model, suggesting that CLL is a multifactorial disease. Our work with the de novo NZB model has revealed many similarities to the human situation, particularly familial CLL. In NZB, the malignant clones express CD5, zap-70, and have chromosomal instability and germline Ig sequence. We also identified a point mutation in the 3'-flanking sequence of Mirn16-1, which resulted in decreased levels of the microRNA, miR-16 in lymphoid tissue. Exogenous restoration of miR-16 to an NZB malignant B-1 cell line resulted in cell cycle alterations, suggesting that the altered expression of Mirn15a/16-1 is an important molecular lesion in CLL. Future studies utilizing the NZB mouse could ascertain the role of environmental triggers, such as low dose radiation and organic chemicals in the augmentation of a pre-existing propensity to develop CLL.


Subject(s)
Disease Models, Animal , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , MicroRNAs/genetics , RNA, Neoplasm/genetics , Animals , Base Sequence , Mice , Mice, Inbred NZB , Mice, Transgenic , Molecular Sequence Data , Point Mutation
SELECTION OF CITATIONS
SEARCH DETAIL
...